vs
AeroVironment Inc（AVAV）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是AeroVironment Inc的1.6倍（$772.1M vs $472.5M），Revvity净利率更高（12.7% vs -3.6%，领先16.4%），AeroVironment Inc同比增速更快（181.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-55.9M），过去两年AeroVironment Inc的营收复合增速更高（59.1% vs 9.0%）
AeroVironment是1971年由人力飞机设计师保罗·麦克里迪创立的美国国防科技企业，总部位于弗吉尼亚州阿灵顿，专注于自主系统、反无人机系统及航天系统的研发制造，为美国国防部及多国军方供应渡鸦、弹簧刀、黄蜂、美洲狮等系列中小型无人机产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AVAV vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$472.5M
营收增速更快
AVAV
高出176.0%
5.9%
净利率更高
RVTY
高出16.4%
-3.6%
自由现金流更多
RVTY
多$217.7M
$-55.9M
两年增速更快
AVAV
近两年复合增速
9.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $472.5M | $772.1M |
| 净利润 | $-17.1M | $98.4M |
| 毛利率 | 22.0% | — |
| 营业利润率 | -6.4% | 14.5% |
| 净利率 | -3.6% | 12.7% |
| 营收同比 | 181.9% | 5.9% |
| 净利润同比 | -875.1% | 3.9% |
| 每股收益（稀释后） | $-0.34 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVAVRVTY
| Q4 25 | $472.5M | $772.1M | ||
| Q3 25 | $454.7M | $698.9M | ||
| Q2 25 | $275.1M | $720.3M | ||
| Q1 25 | $167.6M | $664.8M | ||
| Q4 24 | $188.5M | $729.4M | ||
| Q3 24 | $189.5M | $684.0M | ||
| Q2 24 | $197.0M | $691.7M | ||
| Q1 24 | $186.6M | $649.9M |
净利润AVAVRVTY
| Q4 25 | $-17.1M | $98.4M | ||
| Q3 25 | $-67.4M | $46.7M | ||
| Q2 25 | $16.7M | $53.9M | ||
| Q1 25 | $-1.8M | $42.2M | ||
| Q4 24 | $7.5M | $94.6M | ||
| Q3 24 | $21.2M | $94.4M | ||
| Q2 24 | $6.0M | $55.4M | ||
| Q1 24 | $13.9M | $26.0M |
毛利率AVAVRVTY
| Q4 25 | 22.0% | — | ||
| Q3 25 | 20.9% | 53.6% | ||
| Q2 25 | 36.5% | 54.5% | ||
| Q1 25 | 37.7% | 56.5% | ||
| Q4 24 | 39.1% | — | ||
| Q3 24 | 43.0% | 56.3% | ||
| Q2 24 | 38.4% | 55.7% | ||
| Q1 24 | 36.1% | 54.6% |
营业利润率AVAVRVTY
| Q4 25 | -6.4% | 14.5% | ||
| Q3 25 | -15.2% | 11.7% | ||
| Q2 25 | 5.0% | 12.6% | ||
| Q1 25 | -1.8% | 10.9% | ||
| Q4 24 | 3.7% | 16.3% | ||
| Q3 24 | 12.2% | 14.3% | ||
| Q2 24 | 3.0% | 12.4% | ||
| Q1 24 | 7.7% | 6.8% |
净利率AVAVRVTY
| Q4 25 | -3.6% | 12.7% | ||
| Q3 25 | -14.8% | 6.7% | ||
| Q2 25 | 6.1% | 7.5% | ||
| Q1 25 | -1.0% | 6.4% | ||
| Q4 24 | 4.0% | 13.0% | ||
| Q3 24 | 11.2% | 13.8% | ||
| Q2 24 | 3.1% | 8.0% | ||
| Q1 24 | 7.4% | 4.0% |
每股收益（稀释后）AVAVRVTY
| Q4 25 | $-0.34 | $0.86 | ||
| Q3 25 | $-1.44 | $0.40 | ||
| Q2 25 | $0.59 | $0.46 | ||
| Q1 25 | $-0.06 | $0.35 | ||
| Q4 24 | $0.27 | $0.77 | ||
| Q3 24 | $0.75 | $0.77 | ||
| Q2 24 | $0.18 | $0.45 | ||
| Q1 24 | $0.50 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $588.5M | $919.9M |
| 总债务越低越好 | $747.5M | — |
| 股东权益账面价值 | $4.4B | $7.3B |
| 总资产 | $5.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.17× | — |
8季度趋势，按日历期对齐
现金及短期投资AVAVRVTY
| Q4 25 | $588.5M | $919.9M | ||
| Q3 25 | $685.8M | $931.4M | ||
| Q2 25 | $40.9M | $991.8M | ||
| Q1 25 | $47.0M | $1.1B | ||
| Q4 24 | $69.0M | $1.2B | ||
| Q3 24 | $81.2M | $1.2B | ||
| Q2 24 | $73.3M | $2.0B | ||
| Q1 24 | $107.7M | $1.7B |
总债务AVAVRVTY
| Q4 25 | $747.5M | — | ||
| Q3 25 | $747.5M | — | ||
| Q2 25 | $30.0M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $17.5M | — | ||
| Q2 24 | $28.0M | — | ||
| Q1 24 | $40.0M | — |
股东权益AVAVRVTY
| Q4 25 | $4.4B | $7.3B | ||
| Q3 25 | $4.4B | $7.4B | ||
| Q2 25 | $886.5M | $7.6B | ||
| Q1 25 | $861.1M | $7.6B | ||
| Q4 24 | $858.4M | $7.7B | ||
| Q3 24 | $845.5M | $7.9B | ||
| Q2 24 | $822.7M | $7.9B | ||
| Q1 24 | $813.0M | $7.8B |
总资产AVAVRVTY
| Q4 25 | $5.6B | $12.2B | ||
| Q3 25 | $5.6B | $12.1B | ||
| Q2 25 | $1.1B | $12.4B | ||
| Q1 25 | $1.0B | $12.4B | ||
| Q4 24 | $1.0B | $12.4B | ||
| Q3 24 | $999.2M | $12.8B | ||
| Q2 24 | $1.0B | $13.4B | ||
| Q1 24 | $980.3M | $13.4B |
负债/权益比AVAVRVTY
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 0.02× | — | ||
| Q3 24 | 0.02× | — | ||
| Q2 24 | 0.03× | — | ||
| Q1 24 | 0.05× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-45.1M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-55.9M | $161.8M |
| 自由现金流率自由现金流/营收 | -11.8% | 21.0% |
| 资本支出强度资本支出/营收 | 2.3% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-240.7M | $509.4M |
8季度趋势，按日历期对齐
经营现金流AVAVRVTY
| Q4 25 | $-45.1M | $182.0M | ||
| Q3 25 | $-123.7M | $138.5M | ||
| Q2 25 | $-264.0K | $134.3M | ||
| Q1 25 | $-25.8M | $128.2M | ||
| Q4 24 | $-3.6M | $174.2M | ||
| Q3 24 | $28.4M | $147.9M | ||
| Q2 24 | $-11.7M | $158.6M | ||
| Q1 24 | $52.6M | $147.6M |
自由现金流AVAVRVTY
| Q4 25 | $-55.9M | $161.8M | ||
| Q3 25 | $-146.5M | $120.0M | ||
| Q2 25 | $-8.8M | $115.5M | ||
| Q1 25 | $-29.6M | $112.2M | ||
| Q4 24 | $-8.7M | $149.8M | ||
| Q3 24 | $22.9M | $125.6M | ||
| Q2 24 | $-20.8M | $136.6M | ||
| Q1 24 | $48.8M | $129.7M |
自由现金流率AVAVRVTY
| Q4 25 | -11.8% | 21.0% | ||
| Q3 25 | -32.2% | 17.2% | ||
| Q2 25 | -3.2% | 16.0% | ||
| Q1 25 | -17.7% | 16.9% | ||
| Q4 24 | -4.6% | 20.5% | ||
| Q3 24 | 12.1% | 18.4% | ||
| Q2 24 | -10.5% | 19.7% | ||
| Q1 24 | 26.1% | 20.0% |
资本支出强度AVAVRVTY
| Q4 25 | 2.3% | 2.6% | ||
| Q3 25 | 5.0% | 2.6% | ||
| Q2 25 | 3.1% | 2.6% | ||
| Q1 25 | 2.3% | 2.4% | ||
| Q4 24 | 2.7% | 3.4% | ||
| Q3 24 | 2.9% | 3.3% | ||
| Q2 24 | 4.6% | 3.2% | ||
| Q1 24 | 2.0% | 2.7% |
现金转化率AVAVRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | -0.02× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | -0.48× | 1.84× | ||
| Q3 24 | 1.34× | 1.57× | ||
| Q2 24 | -1.93× | 2.87× | ||
| Q1 24 | 3.79× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVAV
| Services | $130.2M | 28% |
| Cost Plus | $95.8M | 20% |
| Uncrewed Aircraft Systems | $89.8M | 19% |
| Space And Directed Energy | $53.2M | 11% |
| Non U.s.Government | $42.2M | 9% |
| TM | $31.9M | 7% |
| Other | $30.7M | 7% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
